Pressure BioSciences, Inc. · OTC:PBIO
Pressure BioSciences — Investor Presentation (March 2017)
21 slides from Pressure BioSciences's investor presentation, March 2017
Slide 1: Investor Presentation – Pressure BioSciences, Inc.
Investor Presentation Pressure BioSciences, Inc. (OTCQB: PBIO) Discovery Starts with Sample Preparation™ Investor Presentation March 2017 Richard T. Schumacher Founder, President, and CEO
Slide 2: Forward Looking Statements
Forward Looking Statements This presentation may contain forward looking statements that reflect management’s current views and opinions as to the status of the Company’s products, technology and other future events and operations. These statements are neither a promise nor guarantee, but involve ri
Slide 3: Company Overview (OTCQB: PBIO)
Company Overview (OTCQB: PBIO) • 10 FT Staff; Near Boston, MA; Publicly Traded (OTCQB: PBIO) • 15 Patents: Pressure Cycling Technology (“PCT”) Platform • Develop, Mfg, & Sell PCT-based Instruments & Consumables • Initial Focus in Sample Preparation for the Research Market • ~ 275 PCT Systems Install
Slide 4: Experienced Senior Management & Board
Experienced Senior Management & Board Management • Mr. Richard T. Schumacher, President & CEO Boston Biomedica (CEO, Founder); Panacos Pharma (President, Co-founder); Trinity Biotech (Founding Group); CBR Labs (Gen’l Mgr) - Harvard Medical School • Dr. Edmund Y. Ting, Senior VP of Engineering Avure
Slide 5: Pressure Cycling Technology (PCT) for Biomolecular Sample Preparation
PrimaryPressure Sample Preparation CyclingforTechnology Biomolecular (PCT) Analysis: Cell Lysis 5
Slide 6: Sample Input Quality = Sample Result Quality
Sample Input Quality = Sample Result Quality n Quality Quality Sample Sample Preparation Results Scientific research can be broken down to three key elements: sample preparation, analysis, & data reduction/interpretation “Discovery Starts with Sample Preparation” 6
Slide 7: Value Proposition: PCT-based Biological Sample Preparation
Value Proposition: PCT-based Biological Sample Preparation • Analysis of DNA, RNA, Proteins, & Lipids (“biomolecules”) is Crucial to the Discovery of New Biomarkers – Quality of Results Depends on the Quality of Preparation • Biological Sample Preparation is a Multi-Billion Market Comprised of an Es
Slide 8: Biomarker/Forensics Market: Estimated Size
Biomarker/Forensics Market: Estimated Size Estimated Market • Genomics (DNA/RNA) $7.1B in 2015 b • Next Gen Sequencing (DNA) $2.7B in 2017c • Mass Spectrometry (Proteins) $2.7B in 2011a,d • Forensic Tools and Products (DNA) $17.7B in 2019 e • Sample Prep for all OMICS: $8.4B in 2016 f • 500,000 Scie
Slide 9: Selected Marquee Customers (150)
Selected Marquee Customers (150) 9
Slide 10: Just Released: PCT Sample Preparation System
PCT Sample Preparation System Just Released ‼ Barocycler™ NEP2320 PULSE Tube Barocycler™ 2320 EXTREME MicroTubes PCT-dependent Kits 10
Slide 11: PCT Platform: Enabling the Enablers
PCT Platform: Enabling the Enablers Eight Impact Areas Where PBI’s Powerful and Enabling PCT Platform is Currently Being Used… 1. Agriculture/Food Science 2. Environmental Epidemiology 3. Anti-Bioterror 4. Rational Drug Design 5. Biomarker Discovery 6. Fecal Lipidomic Profiling 7. Personalized Medic
Slide 12: Rational Drug Design and Development
Rational Drug Design and Development Professor Wayne L. Hubbell UCLA • Distinguished Professor of Biochemistry • Member, National Academy of Sciences • Fellow, American Academy of Arts and Sciences Molecular structure of a protein and the conformational changes that control its function are key to b
Slide 13: Biomarker Discovery
Biomarker Discovery Professor Jennifer Van Eyk Cedars-Sinai Medical Center • Professor Of Medicine • Director, Basic Science Research, the Barbara Streisand Women’s HC • Over 1 billion archived formalin-fixed paraffin-embedded (FFPE) samples • Combination of heat and elevated pressure increased prot
Slide 14: Non-invasive Fecal Lipidomic Profiling
Non-invasive Fecal Lipidomic Profiling Professor Bruce Kristal Harvard Medical School • Neuroscientist, Brigham and Women's Hospital, Boston • Associate Professor of Neurosurgery, • Molecular Biologist, Expert in Metabolomics • Better analysis of fecal material will facilitate the understanding of g
Slide 15: Improved Rape Kit Testing
Improved Rape Kit Testing Professor Bruce McCord Florida Int’l University • Professor of Analytical/Forensic Chemistry, • Over 75 peer reviewed papers and 11 book chapters An estimated 400,000 untested rape kits in the USA (The Dark Side of Clearing America’s Rape Kit Back-log, Time Magazine 2013) •
Slide 16: Personalized Medicine: Analysis of Tissue Biopsies
Personalized Medicine: Analysis of Tissue Biopsies Professor Ruedi Aebersold •Inst of Molec Sys Biology - ETH Zurich • Professor of Systems Biology • Scientific Advisory Committee of numerous public and private research organizations; member of several editorial boards in proteomics & genomics Rapid
Slide 17: Mr. David Weild IV, Weild & Co. Holdings
Mr. David Weild IV Weild & Co. Holdings CEO, Co-Founder • Former Vice-Chairman of NASDAQ • “Father of the JOBS Act” (Forbes Mag) • Former Head of Global Equity Transactions, Prudential Securities • Former President, PrudentialSecurities.com • Former Head, Capital Markets Group of Grant Thornton LLP
Slide 18: Key Achievements: 2016
Key Achievements: 2016 • Q1: Close of Over-Subscribed $5M PIPE at $6.3M • Q1: 100% (almost $3M) of all Variable Rate Debt Eliminated • Q1: Co-Marketing Partner Announced (Jan): SCIEX! • Global leader in life sciences analytical technologies, incl. Mass Spec • Wholly-owned subsidiary of the Danaher C
Slide 19: Children's Medical Research Institute (Australia)
Children’s Medical Research Institute (Australia) SCIEX Announces Alliance with CMRI on Feb 3, 2016 CMRI Designated Official Collaborator – US Cancer Moonshot – by VP Joe Biden on July 16, 2016 • CMRI will test 70,000 tumor samples by PCT-SWATH • CMRI has purchased 4 SCIEX MSs, 3 PBI Barocyclers & P
Slide 20: Initial Commercial Application: Mass Spectrometry
Initial Commercial Application: Mass Spectrometry (“First Killer App”) The Following Information is for Discussion Purposes Only – Not Guidance Biomarker Discovery (Enhanced Mass Spectrometry Sample Preparation) We Believe: • there are approximately 16,000 MS labs worldwide • most MS protein analyse
Slide 21: Short-term Growth Drivers
Short-term Growth Drivers • Exclusive, 2-Year, WW, Co-Marketing Agreement with Global Leader SCIEX • 100% of Floorless Debt Eliminated; $2M Line Closed; $610K PIPE Close • 2017 M$S Expansion: 4+ Additions in Sales & Marketing • Company Expects Continued Strong Revenue Growth • Company Considering Up
Pressure BioSciences — Investor Presentation (March 2017) on 6ix